Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.52 EUR | +1.67% | -3.84% | +79.37% |
Apr. 05 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
Mar. 28 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 51.33M 55.67M | Sales 2025 * | 58.9M 63.88M | Capitalization | 70.97M 76.97M |
---|---|---|---|---|---|
Net income 2024 * | 1M 1.08M | Net income 2025 * | 3M 3.25M | EV / Sales 2024 * | 1.18 x |
Net cash position 2024 * | 10.53M 11.42M | Net cash position 2025 * | 10.63M 11.53M | EV / Sales 2025 * | 1.02 x |
P/E ratio 2024 * |
54.4
x | P/E ratio 2025 * |
19.2
x | Employees | 177 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98% |
Latest transcript on Apontis Pharma AG
1 day | +1.67% | ||
1 week | -3.84% | ||
1 month | +3.15% | ||
3 months | +34.81% | ||
6 months | +114.61% | ||
Current year | +79.37% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | - | |
Director of Finance/CFO | - | 21-12-31 | |
Olaf Randerath
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Edin Hadzic
BRD | Director/Board Member | 53 | 20-12-31 |
Olaf Elbracht
BRD | Director/Board Member | 59 | 20-12-31 |
Chairman | 51 | 20-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 8.52 | +1.67% | 10,086 |
24-05-30 | 8.38 | +2.44% | 5,063 |
24-05-29 | 8.18 | -2.39% | 3,282 |
24-05-28 | 8.38 | -4.56% | 11,175 |
24-05-27 | 8.78 | -0.90% | 5,178 |
Delayed Quote Xetra, May 31, 2024 at 11:36 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+79.37% | 76.97M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- APPH Stock